Skip to content
value.today

Erasca, Inc.

🇺🇸 San Diego, California, USABiotechnologyFounded 2018
Total raised
$184 M
2 rounds on record
Latest round
$125 M
Apr 2020
First round on record
Oct 2018
Today
Went public
See the company page

Erasca, Inc. is listed today as Erasca, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Erasca, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2020$125 MNo. 2$50 to $250 million

Erasca, Inc.: Raise no. 2, Apr 2020

Investors in this round

46 investors had bought by the notice of Apr 30, 2020: 46 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for Erasca, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$125 M of $375 M offered; $249 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jonathan E. Lim, M.D. · Executive Officer, Director · Executive Chairman, CEO, President, Treasurer, Secretary
  • Alexander W. Casdin · Director
  • James A. Bristol, Ph.D. · Director
  • Jonathan E. Lim, M.D. · Director
  • Pratik S. Multani, M.D. · Director
  • Valerie S. Harding-Start · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jonathan E. Lim, M.D., President. Source: SEC Form D, newest notice filed Apr 30, 2020. Read the notice at the SEC.

equitySEC
Oct 2018$58 MNo. 1$50 to $250 million

Erasca, Inc.: Raise no. 1, Oct 2018

Investors in this round

41 investors had bought by the notice of Mar 11, 2019: 41 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for Erasca, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$58 M of $70 M offered; $12 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gary E. Yeung, CFA · Executive Officer · Chief Business Officer
  • Jonathan E. Lim, M.D. · Executive Officer, Director · President and Executive Chairman
  • Alexander W. Casdin · Director
  • James A. Bristol, Ph.D. · Director
  • Pratik S. Multani, M.D. · Director
  • Valerie S. Harding-Start · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jonathan E. Lim, M.D., President. Source: SEC Form D and 1 amendment, newest notice filed Mar 11, 2019. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Erasca, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2020).

    SEC Form D · Apr 2020

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Apr 2020

That is all the official record says: Erasca, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Erasca, Inc. are on record.

Investors#

10 named in official filings. Open an investor to see everything it has backed.

Investors in Erasca, Inc.
InvestorKindAmountRoundRoleSource
Alexander W. CasdinPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2021)SEC Form 3
ARCH Venture Fund X, L.P.Venture capitalnot statednot statedHeld Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
ARCH Venture Fund X Overage, L.P.Venture capitalnot statednot statedHeld Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
ARCH Venture Partners X, LLCVenture capitalnot statednot statedHeld Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
ARCH Venture Partners X, L.P.Venture capitalnot statednot statedHeld Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
ARCH Venture Partners X Overage, L.P.Venture capitalnot statednot statedHeld Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
City Hill, LLCOthernot statednot statedHeld Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Cormorant Asset Management, LPFund or asset managernot statednot statedHeld Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Cormorant Global Healthcare Master Fund, LPFund or asset managernot statednot statedHeld Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Cormorant Private Healthcare Fund II, LPFund or asset managernot statednot statedHeld Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 46 investors.

Largest shareholders today

Institutions holding Erasca, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Erasca, Inc.
NameRoleNamed in
Jonathan E. Lim, M.D.Executive Chairman, CEO, President, Treasurer, SecretaryApr 2020
Gary E. Yeung, CFAChief Business OfficerMar 2019
Gary Yeung, CFAChief Business OfficerJan 2019
Jonathan Lim, M.D.President and Executive ChairmanJan 2019
Alexander W. CasdinDirectorApr 2020
James A. Bristol, Ph.D.DirectorApr 2020
Jonathan E. Lim, M.D.DirectorApr 2020
Pratik S. Multani, M.D.DirectorApr 2020
Valerie S. Harding-StartDirectorApr 2020
Jonathan Lim, M.D.President and Executive ChairmanJan 2019

Went public since 2021. Its SEC number is that of a company listed on a stock exchange.